Amy Schmidt, MD
Hematology & Oncology · Denver, CONPI 1053509109
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,772,561 of the $2,773,305 with a category attached, or 100.0%. CSL Behring accounts for 100.0% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2021 at $984,750 and has fallen 100.0% since, to $69 in 2025. Among hematology & oncology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 409 payments — averaging $6780.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$2.8M
- Sanofi$675
- Haemonetics Corporation$49
- Sanofi-aventis U.S. LLC$20
What the payments were for
- Consulting fees$2,772,561100%
- Speaking & faculty fees$6750%
- Food & beverage$690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 405 | $2,772,561 |
| Sanofi | 2 | $675 |
| Haemonetics Corporation | 1 | $49 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NO PRODUCT DISCUSSED$375
- CERDELGA$300
How this compares
$2,773,305 in reported general payments places this provider in the 95th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Denver
- Yousuf GaffarDenver$963K
- Robert RifkinDenver$270K
- Mabel MardonesDenver$149K
- Peter ForsbergDenver$147K
- Peter McSweeneyDenver$126K
- Alireza EghtedarDenver$96K
- Jeffrey MatousDenver$93K
- Tara GregoryDenver$67K
- Michael TeesDenver$56K
- Marcello RottaDenver$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.